BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518931-12-00

Acronym

RG_11-087

Enrollment

122

Registered

2024-11-13

Start date

2014-05-15

Completion date

Unknown

Last updated

2024-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Brief summary

Best response (Complete Response [CR], or Partial Response [PR](Brodeur et al. 1988) at any time during the first 6 cycles of trial treatment, For the bevacizumab part 2 only: Progression-free survival (PFS)

Detailed description

Safety of the regimens: Incidence and severity of Adverse Events (AE), PFS, Event-free survival (EFS), Overall survival (OS)

Interventions

DRUGTEMOZOLOMIDE

DRUGDINUTUXIMAB BETA

DRUGIRINOTECAN

DRUGBEVACIZUMAB

DRUGCYCLOPHOSPHAMIDE

DRUGTOPOTECAN

Eligibility

Sex/Gender

All

Age

0 Years to 17 Years

Design outcomes

Primary

Measure	Time frame
Best response (Complete Response [CR], or Partial Response [PR](Brodeur et al. 1988) at any time during the first 6 cycles of trial treatment, For the bevacizumab part 2 only: Progression-free survival (PFS)	—

Secondary

Measure	Time frame
Safety of the regimens: Incidence and severity of Adverse Events (AE), PFS, Event-free survival (EFS), Overall survival (OS)	—

Countries

Belgium, Denmark, France, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026